Chronic obstructive pulmonary disease (COPD) is increasingly recognized as a heterogeneous syndrome with distinct phenotypes—clinically observable characteristics that, alone or in combination, describe differences between individuals related to clinically meaningful outcomes—and endotypes (underlying biological mechanisms). The 2023 GOLD report acknowledges this heterogeneity and supports phenotype-targeted therapy. Phenotype classification serves to predict prognosis, identify therapeutic responders, and personalize treatment. Established and emerging phenotypes include: emphysema-predominant (parenchymal destruction, panacinar or centrilobular pattern, hyperinflation, low DLCO, severe dyspnea, lower BMI; CT shows emphysema; 'pink puffer' historic terminology); chronic bronchitis-predominant (mucus hypersecretion, productive cough ≥3 months/year for 2 years, normal or modest hyperinflation, more comorbid OSA, 'blue bloater' historically); frequent exacerbator (≥2 moderate or 1 severe exacerbation per year, distinct biology with persistent inflammation, accelerated lung function decline, worse mortality, eligible for ICS).
Asthma-COPD overlap (ACO): features of both diseases—post-bronchodilator FEV1/FVC <0.70 with significant reversibility (≥400 mL or ≥12%), elevated eosinophils, elevated FeNO, atopy/allergic rhinitis, often nonsmoker or light smoker, often responsive to ICS; eosinophilic phenotype: blood eosinophils ≥300/µL identify ICS-responsive subgroup with reduced exacerbations on ICS, also identifies candidates for emerging biologics (IL-5/IL-5R, IL-4R, TSLP); alpha-1 antitrypsin deficiency phenotype: AAT serum level <11 µM (typically <80 mg/dL), homozygous PiZZ or compound heterozygous, basal-predominant panacinar emphysema, often diagnosed under age 50, family history; AAT augmentation therapy (Prolastin, Aralast, Glassia, Zemaira—pooled human AAT IV weekly) slows emphysema progression in selected patients; pulmonary cachexia: BMI <21 kg/m², muscle wasting, increased mortality independent of FEV1, requires nutritional and rehabilitative intervention; rapid decliners: FEV1 decline >40 mL/year, identifies aggressive disease; persistent airflow limitation in young adults: childhood asthma persisting; bronchiectasis-COPD overlap: HRCT bronchiectasis with chronic infection, often Pseudomonas, increased exacerbations.
Phenotype-guided therapy: emphysema-predominant—LAMA + LABA bronchodilators, lung volume reduction (surgery, endobronchial valves) for advanced; chronic bronchitis—LAMA + LABA, mucolytics (N-acetylcysteine, carbocysteine, erdosteine), roflumilast for severe with exacerbations; frequent exacerbator with eosinophils ≥300—triple therapy (LAMA/LABA/ICS), azithromycin for non-eosinophilic exacerbators; ACO—ICS-containing therapy similar to severe asthma; eosinophilic—ICS responsive, emerging biologics (mepolizumab, benralizumab, dupilumab in trials); alpha-1 deficiency—AAT augmentation, smoking cessation absolute, lung transplant for advanced; pulmonary cachexia—nutritional support, anabolic strategies, pulmonary rehabilitation. All phenotypes benefit from smoking cessation, vaccinations (influenza, pneumococcal, RSV), pulmonary rehabilitation, and oxygen for hypoxemia. Clinical biomarkers (blood eosinophils, FeNO, AAT level, FEV1 decline rate, CT pattern) and emerging endotype tools (sputum cytokines, microbiome, genomics) refine phenotype assignment.